跳至主要内容
临床试验/NCT04569734
NCT04569734已完成不适用

Safety and Feasibility of Intra-Cardiac Echocardiography in Guiding Left Atrial Appendage Occlusion With the Watchman Device: The ICE WATCHMAN Study (Data Coordinating Center)

Mayo Clinic2 个研究点 分布在 1 个国家目标入组 101 人开始时间: 2020年9月22日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
Mayo Clinic
入组人数
101
试验地点
2
主要终点
Successfully implant the WATCHMAN device

研究概览

简要总结

The aim of this multi-center study will be to assess the feasibility and safety of left atrial appendage (LAA) occlusion with the WATCHMAN™ device using a standardized intra-procedural intracardiac echocardiography (ICE) protocol under moderate sedation for procedural guidance. By eliminating the need for general anesthesia, the hope is to show a reduction in procedural time, decrease use of supplemental invasive procedures (central venous line, invasive arterial pressure monitoring and transesophageal echocardiography) and quicker patient recovery time. This approach can decrease healthcare resource utilization and safely simplify left atrial appendage closure with the WATCHMAN device.

详细描述

The study will be a prospective, non-randomized multicenter registry of 100 patients undergoing LAA closure with the WATCHMAN device (possibly with WATCHMAN FLX when approved) utilizing an intra-procedural ICE probe under moderate sedation. The primary feasibility endpoint will be ability to successfully implant the WATCHMAN device. Implant success is defined as confirmation of the device-specified release PASS (Position, Anchor, Size, Seal) criteria, successful device release, and adequate seal (defined as a residual leak <5 mm) as assessed by a core lab interpretation of the TEE 45 days post-implant. The primary safety endpoint will be a composite of major complications (major bleeding [intracranial bleeding, or bleeding requiring blood transfusion], pericardial effusion requiring pericardiocentesis or surgery, device embolization, procedural-related stroke, or procedural related death). Additional measured end points will be: freedom from conversion to general anesthesia and/or standard TEE during implant, the incidence and the size of iatrogenic atrial septal defect on 45 day TEE. The ICE procedural images will also be collected and analyzed by an independent committee composed of non-implanting interventionalist, and an imaging specialist. The images will be graded in quality as optimal (TEE equivalent), acceptable (adequate but not as detailed as TEE), and inadequate. This prospective study, along with its endpoints will be registered in clinicaltrials.gov.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • The patients is eligible to undergo WATCHMAN device implant procedure
  • The patient is eligible for short term anticoagulation therapy
  • Ability to tolerate the procedure without the need for general anesthesia as assessed by the treating physician(s)
  • Ability to give informed consent for the procedure
  • The patient is able and willing to undergo the procedure under moderate sedation
  • The patient is able and willing to return for required 45-day TEE.

排除标准

  • Patient has contraindication for short term anticoagulation
  • The patient has history of a hypercoagulable state per medical record documentation
  • Pregnancy or planning to get pregnant during the investigation.

结局指标

主要结局

Successfully implant the WATCHMAN device

时间窗: 45 days post-implant

Implant success is defined as confirmation of the device-specified release PASS (Position, Anchor, Size, Seal) criteria, successful device release, and adequate seal (defined as a residual leak \<5 mm) as assessed by a core lab interpretation of the TEE 45 days post-implant

Absence of a composite of major complications

时间窗: 45 days post-implant

Absence of a composite of major complications such major bleeding \[intracranial bleeding, or bleeding requiring blood transfusion\], pericardial effusion requiring pericardiocentesis or surgery, device embolization, procedural-related stroke, or procedural related death)

次要结局

  • Freedom from the incidence and the size of iatrogenic atrial septal defect(45 days post-implant)
  • Freedom from conversion to general anesthesia and/or standard TEE during implant(During procedure)

研究者

发起方
Mayo Clinic
申办方类型
Other
责任方
Principal Investigator
主要研究者

Mohamad Adnan Alkhouli

Principal Investigator

Mayo Clinic

研究点 (2)

Loading locations...

相似试验